Hutchison China Meditech Ltd. (Chi-Med), of Hong Kong, said the first patient was dosed in a phase I/II trial of HMPL-453, a small-molecule inhibitor targeting fibroblast growth factor receptor (FGFR), in China. The phase I portion will evaluate HMPL-453 in a dose-escalation stage that will enroll patients with locally advanced or metastatic solid tumors, for whom standard therapy either does not exist or has proved to be ineffective or intolerable, regardless of genetic status, to determine the maximum tolerated dose and recommended phase II dose (PR2D).